Abstract
Despite relative stable and adequately controlled background pain, Breakthrough Cancer Pain (BTcP) is a transient exarcebation of pain that occurs either spontaneously or in relation to a specific predictable trigger. It is characterized by a typical temporal pattern which includes a short onset (generally a few minutes) and a short duration (30-90 minutes). It has a strong influence on quality of life (QoL), including detrimental effects on activities of daily living, sleep, social relationships and enjoyment of life. Therefore, BTcP represents an important clinical challenge in the care of patients with cancer. Transmucosal fentanyl, a rapid onset opioid (ROO), is indicated for the treatment of BTcP in patients who are already receiving and are tolerant to opioid therapy for underlying, persistent pain. In order to identify published studies on BTcP and ROOs a Medline search was carried out. The characteristics of the various formulations of transmucosal fentanyl used for BTcP and clinical data published in literature will be described in this review.
Keywords: Breakthrough cancer pain, fentanyl, transmucosal delivery, rapid onset opioid, hydromorphon, subcutaneous route, transmucosal, bioavailability, morphine, nasal
Reviews on Recent Clinical Trials
Title:Fentanyl for Breakthrough Cancer Pain: Where are We?
Volume: 8 Issue: 1
Author(s): Fausto Meriggi and Alberto Zaniboni
Affiliation:
Keywords: Breakthrough cancer pain, fentanyl, transmucosal delivery, rapid onset opioid, hydromorphon, subcutaneous route, transmucosal, bioavailability, morphine, nasal
Abstract: Despite relative stable and adequately controlled background pain, Breakthrough Cancer Pain (BTcP) is a transient exarcebation of pain that occurs either spontaneously or in relation to a specific predictable trigger. It is characterized by a typical temporal pattern which includes a short onset (generally a few minutes) and a short duration (30-90 minutes). It has a strong influence on quality of life (QoL), including detrimental effects on activities of daily living, sleep, social relationships and enjoyment of life. Therefore, BTcP represents an important clinical challenge in the care of patients with cancer. Transmucosal fentanyl, a rapid onset opioid (ROO), is indicated for the treatment of BTcP in patients who are already receiving and are tolerant to opioid therapy for underlying, persistent pain. In order to identify published studies on BTcP and ROOs a Medline search was carried out. The characteristics of the various formulations of transmucosal fentanyl used for BTcP and clinical data published in literature will be described in this review.
Export Options
About this article
Cite this article as:
Meriggi Fausto and Zaniboni Alberto, Fentanyl for Breakthrough Cancer Pain: Where are We?, Reviews on Recent Clinical Trials 2013; 8 (1) . https://dx.doi.org/10.2174/15748871112079990039
DOI https://dx.doi.org/10.2174/15748871112079990039 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Tumor Effects of 1,25-Dihydroxyvitamin D3 and Vitamin D Analogs
Current Pharmaceutical Design HOX Genes as Potential Markers of Circulating Tumour Cells
Current Molecular Medicine LncRNA HOTAIR as Prognostic Circulating Marker and Potential Therapeutic Target in Patients with Tumor Diseases
Current Drug Targets SENP1 as A Biomarker for the Diagnosis of Cancer: Review of the Science and Published Patents
Recent Patents on Biomarkers The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Nitrogen Mustards as Anticancer Chemotherapies: Historic Perspective, Current Developments and Future Trends
Current Topics in Medicinal Chemistry Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design Review of Cell and Organ Printing Patents
Recent Patents on Biomedical Engineering (Discontinued) Synthesis and Antitumor Evaluation of Thiophene Analogs of Kigelinone
Letters in Organic Chemistry Eosinophils in Cancer: Favourable or Unfavourable?
Current Medicinal Chemistry Key Epigenetic Events Involved in the Maintenance of Breast Cancer Stem Cells
Current Stem Cell Research & Therapy Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry Statins and Type 2 Diabetes Mellitus: An Update After 1 Year
Current Pharmaceutical Design Medicinal Plants from Peru: A Review of Plants as Potential Agents Against Cancer
Anti-Cancer Agents in Medicinal Chemistry A Review on Theragnostic Applications of Micrornas and Long Non- Coding RNAs in Colorectal Cancer
Current Topics in Medicinal Chemistry The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Perspectives in Breast and Ovarian Cancer Chemotherapy by Nanomedicine Approach: Nanoformulations in Clinical Research
Current Medicinal Chemistry Oxidative DNA Damage and Oxidant/Anti-Oxidant Enzymatic Systems in Carcinogenesis and Cancer Progression
Current Enzyme Inhibition